Earlier this week, FDA posted numerous warning letters and untitled letters to the manufacturers and telehealth companies for their marketing practices that are harming our young adult patient community. Among these companies targeted were those marketing unapproved compounded GLP-1s, with FDA labeling their products as misbranded. FDA also sent warning letters to manufacturers of approved GLP-1s who have been engaging in […]

Generation Patient welcomes today’s White House announcement of increased oversight and enforcement against deceptive direct-to-consumer (DTC) pharmaceutical advertising on social media platforms.

Have you noticed an increase in medication-related advertisements on your social media? Are the ads targeting your symptoms? Do you feel influenced to buy the medication online?

On June 30th, 2025, our Executive Director, Sneha Dave had the opportunity to represent our young adult patient community at a listening session hosted by the Federal Trade Commission (FTC) and U.S. Department of Justice (DOJ) focused on solutions to lower prescription prices for patients. In the session, Sneha explained to regulators the issues our community faces in accessing pharmaceutical therapeutics, including the 21% of Americans aged […]

Generation Patient, an organization committed to supporting young adults with chronic and rare conditions through community support and policy change, announced its endorsement of Eliminating Thickets to Increase Competition Act (ETHIC Act). Senators Peter Welch (D-VT), Josh Hawley (R-MO), and Amy Klobuchar (D-MN) introduced this bipartisan legislation to address […]

Peer support is a crucial part of our work at Generation Patient. Through our peer support programming, we aim to build community, reduce isolation, and ensure that young adults with chronic conditions have a space to explore their chronic illness identity. We offer eight peer groups per month, spanning three regions of the world, and complement this direct support work with […]

This week, the Trump Administration issued a new Executive Order introducing a “Most Favored Nation” (MFN) policy aimed at reducing prescription drug prices in the United States. The MFN policy seeks to align U.S. drug prices with those paid in other developed countries, where Americans often pay two to three times more for the same medications. The order directs federal […]

Serial patent litigation refers to a branded pharmaceutical company suing a generic pharmaceutical company (i.e., a company that manufactures lower-cost versions of high-cost therapeutics) repeatedly regarding the same generic medication. This process delays the ability to bring generic medications to patients and, in some cases, may completely remove access. […]